<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pinero, Sindy</style></author><author><style face="normal" font="default" size="100%">Li, Xiaomei</style></author><author><style face="normal" font="default" size="100%">Liu, Lin</style></author><author><style face="normal" font="default" size="100%">Li, Jiuyong</style></author><author><style face="normal" font="default" size="100%">Lee, Sang Hong</style></author><author><style face="normal" font="default" size="100%">Le, Thuc Duy</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">SPLIT: Safety Prioritization for Long COVID Drug Repurposing via a Causal Integrated Targeting Framework</style></title><secondary-title><style face="normal" font="default" size="100%">medRxiv</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2026-01-01 00:00:00</style></date></pub-dates></dates><elocation-id><style  face="normal" font="default" size="100%">2026.04.12.26350701</style></elocation-id><doi><style  face="normal" font="default" size="100%">10.64898/2026.04.12.26350701</style></doi><volume><style face="normal" font="default" size="100%"></style></volume><issue><style face="normal" font="default" size="100%"></style></issue><abstract><style  face="normal" font="default" size="100%">Long COVID affects millions of people worldwide, yet no disease-modifying treatment has been approved, and existing interventions have shown only modest and inconsistent benefits. A key reason for this limited progress is that current computational drug repurposing pipelines do not match well with the clinical reality of Long COVID. These patients often have persistent, multi-systemic symptoms and may already be taking multiple medications, making treatment safety a primary concern. However, most repurposing workflows still treat safety as a downstream filter and rely on disease-associated targets rather than causal drivers. They also assume that the findings of one analysis would generalize across the diverse presentations of Long COVID. We introduce SPLIT, a safety-first repurposing framework that addresses these limitations. SPLIT prioritizes safety at the start of the candidate evaluation, integrates complementary causal inference strategies to identify likely driver genes, and uses a counterfactual substitution design to compare drugs within specific cohort contexts. When applied to cognitive and respiratory Long COVID cohorts, SPLIT revealed three main findings. First, drugs with similar predicted efficacy could have very different predicted safety profiles. Second, the drugs flagged as unfavorable were often different between the two cohorts, showing that drug prioritization is phenotype-specific. Third, SPLIT flagged 18 drugs currently under active investigation in Long COVID trials as having unfavorable predicted profiles. SPLIT provides a practical framework to identify safer, more context-appropriate candidates earlier in the process, supporting more targeted and better-tolerated treatment strategies for Long COVID.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAll analyses were performed using reproducible workflows in Python 3.11, with environment specifications captured through conda. Data processing, network construction, MR pipelines, DCE implementation, CT analyses, drug--gene mapping, and PlaNet inference are encapsulated in modular scripts and notebooks executable on standard compute or high-performance clusters. All source code, configuration files, and minimal processed input required to reproduce the results are publicly available at \url{https://github.com/SindyPin/SPLIT}, following the principles of open science and FAIR.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll analyses were performed using reproducible workflows in Python 3.11, with environment specifications captured through conda. Data processing, network construction, MR pipelines, DCE implementation, CT analyses, drug--gene mapping, and PlaNet inference are encapsulated in modular scripts and notebooks executable on standard compute or high-performance clusters. All source code, configuration files, and minimal processed input required to reproduce the results are publicly available at \url{https://github.com/SindyPin/SPLIT}, following the principles of open science and FAIR. https://github.com/SindyPin/SPLIT</style></abstract></record></records></xml>